- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04444011
Pharmacokinetic Interactions of Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth
A Single-center, Randomized, Open-label, Crossover Study to Evaluate the Pharmacokinetic Drug-drug Interaction of the Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/Bismuth in Healthy Chinese Male Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1.The subject is capable of understanding and complying with protocol requirements, and signed and dated a written informed consent form voluntarily
- 2.The subject is a Chinese adult male, aged 18 to 35 years, inclusive.
- 3.The subject is a H. pylori-negative via UBT.
- 4.The subject weighed at least 50.0 kg and had a body mass index (BMI) between 19.0 kg/m^2 and 26.0 kg/m^2, inclusive.
- 5.Has clinical laboratory evaluations, vital signs and ECG testing within the reference range, and medical history and physicial examination results are normal. Participants with evaluations outside the reference range that are deemed not clinically significant by the investigator may be included at investigator discretion
- 6.The subject with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 3 months after last dose.
- 7.The subjects have a good lifestyle and can keep good communication with the investigators and comply with the requirements of clinical trial
Exclusion Criteria:
- 1.Has clinical significant drug allergy or allergic disease history(Such as asthma, urticaria, eczema dermatitis, etc), or has hypersensitivity or allergy to investigatory drugs or related supplements;
- 2.Has clinical significant ECG abnormal history or family history of long QT syndrome(Grandparents, parents and siblings)
3.Any disease or medical history that may significantly affect the absorption, distribution, metabolism, and excretion of drugs, or any condition that may pose a hazard to the subject. Such as:
- Inflammatory bowel disease, gastric ulcer, duodenal ulcer, gastrointestinal / rectal bleeding, persistent nausea, or other clinically significant gastrointestinal abnormalities;
- Has suffered from gastrointestinal diseases or complications that may affect the absorption of drugs (ie: malabsorption, gastroesophageal reflux, peptic ulcer, erosive esophagitis, frequent heartburn) within 6 months before screening or had history of gastrointestinal surgery (for example: gastrectomy, gastrointestinal anastomosis, intestinal resection, gastric bypass, gastric segmentation or gastric banding, cholecystectomy, except for appendicitis surgery and proctectomy);
- Evidence of liver disease or clinically impaired liver function at the time of screening (eg AST, ALT or total bilirubin> 1.5 times ULN);
- A history or evidence of nephropathy or renal insufficiency at the time of screening, showing clinically significant abnormality of creatinine or abnormal urine composition (such as proteinuria, creatinine> 176.8 umol / L, etc.)
- Has difficulty swallowing oral preparations.
- 4.Thyroid stimulating hormone (TSH)> ULN; or serum free triiodothyronine (FT3)> ULN; or serum free thyroxine (FT4)> ULN at the time of screening;
- 5. Frequent smokers and alcoholics within 3 months before screening (smoke more than 5 cigarettes / day, drink more than 21 units of alcohol per week, 1 unit = 360 mL beer or 45 mL liquor or 150 mL wine), or can't stop using any tobacco products, and alcohol intake during the study period ; or those who have a positive alcohol breath test before enrollment;
- 6. Has received any investigational compound (including post-marketing investigational drugs) or participated in clinical trials of any drugs /devices within 3 months before screening;
- 7. A history of drug abuse within 12 months before screening or a positive urine test result at screening;
- 8. Has used any prescription drugs, non-prescription drugs (including chemical drugs, vitamin drugs, Chinese herbal medicines, etc.) within 4 weeks before administration of investigational drugs;
- 9. Has taken foods that affect CYP3A4 (such as grapefruit or beverages containing grapefruit) within 2 weeks before administration of investigational drugs;
- 10. Human immunodeficiency virus antibody, hepatitis B surface antigen, hepatitis C antibody, and Treponema pallidum specific antibody test results were positive at screening;
- 11. Has difficulty in venous blood collection or halo acupuncture;
- 12.Blood donation / blood loss ≥200 mL within 1 month, or ≥400 mL within 3 months before screening; or has blood donation plan during the period of medication of investigational drugs and within 3 months after drug withdrawal;
- 13. Has special dietary requirements and cannot follow the unified dietary arrangements;
- 14. Any conditions in which considered by investigator not be appropriate to participate in this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Anaprazole Sodium enteric-coated tablet
Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), one tablet each time.
|
Anaprazole Sodium isthePPI inhibitor
|
EXPERIMENTAL: Amoxicillin capsules
"Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), 2 capsules each time.
|
antibiotic
|
EXPERIMENTAL: Clarithromycin tablet
"Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods of cohort 1 ( only once on the morning of D5 of treatment periods), 2 tablets each time.
|
antibiotic
|
EXPERIMENTAL: Anaprazole + Amoxicillin +Clarithromycin
"Cohort 1: Administered orally twice daily (e.g., 8am,8pm) for 5 consecutive days in 1 of 4 treatment periods ( only once on the morning of D5 of treatment periods). Cohort 2: Administered orally on an empty stomach once on the morning of D1 of treatment periods |
Anaprazole Sodium isthePPI inhibitor
antibiotic
antibiotic
|
EXPERIMENTAL: Anaprazole + Amoxicillin +Clarithromycin+Bismuth
Administered orally on an empty stomach once on the morning of D1 of treatment periods in cohort 2
|
Anaprazole Sodium isthePPI inhibitor
antibiotic
antibiotic
Bismuth is to protect the gastric mucosa
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohort 1: Css,max of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites (KBP-1123 and KBP-1144), Unchanged amoxicillin, Unchanged clarithromycin and its metabolite (14-hydroxyclarithromycin)
Time Frame: Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 5,Day 19,Day 33,Day 47
|
Css,max is the peak plasma concentration at steady state
|
Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 5,Day 19,Day 33,Day 47
|
Cohort 1: AUC of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites (KBP-1123 and KBP-1144), Unchanged amoxicillin, Unchanged clarithromycin and its metabolite (14-hydroxyclarithromycin)
Time Frame: Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 5,Day 19,Day 33,Day 47
|
AUC is area under the plasma concentration-time curve
|
Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 5,Day 19,Day 33,Day 47
|
Cohort 2: Cmax of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites (KBP-1123 and KBP-1144), Unchanged amoxicillin, Unchanged clarithromycin and its metabolite (14-hydroxyclarithromycin)
Time Frame: Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 1,Day 11
|
Cmax is the peak plasma concentration
|
Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 1,Day 11
|
Cohort 2: AUC of anaprazole (parent drug, KBP-3571) and its enantiomer(KBP-3570)and its major metabolites (KBP-1123 and KBP-1144), Unchanged amoxicillin, Unchanged clarithromycin and its metabolite (14-hydroxyclarithromycin)
Time Frame: Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 1,Day 11
|
AUC is area under the plasma concentration-time curve
|
Hour 0.5 pre-dose and 0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,10,12,24 hours post-dose of Day 1,Day 11
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with adverse events and serious adverse events as assessed by CTCAE v5.0
Time Frame: From signing informed consent to study completion. 56 days minimum, 68 days maximum(Cohort 1); 30 days minimum, 32 days maximum(Cohort 2)
|
All adverse events will be monitored in each subject
|
From signing informed consent to study completion. 56 days minimum, 68 days maximum(Cohort 1); 30 days minimum, 32 days maximum(Cohort 2)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3571-DDI-1006
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Male Volunteers
-
Shanghai Henlius BiotechRecruitingHealthy Male VolunteersChina
-
PMV Pharmaceuticals, IncCompleted
-
Hanmi Pharmaceutical Company LimitedCompletedHealthy Male VolunteersKorea, Republic of
-
Hanlim Pharm. Co., Ltd.UnknownHealthy Male VolunteersKorea, Republic of
-
Bristol-Myers SquibbCompletedHealthy Male VolunteersUnited States
-
Daewoong Pharmaceutical Co. LTD.UnknownHealthy Male VolunteersKorea, Republic of
-
Sihuan Pharmaceutical Holdings Group Ltd.CompletedHealthy Male Volunteers
-
Allist Pharmaceuticals, Inc.CompletedHealthy Male VolunteersChina
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male VolunteersKorea, Republic of
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male VolunteersKorea, Republic of
Clinical Trials on Anaprazole Sodium
-
Sihuan Pharmaceutical Holdings Group Ltd.CompletedHealthy Male Volunteers
-
Sihuan Pharmaceutical Holdings Group Ltd.Unknown
-
Sihuan Pharmaceutical Holdings Group Ltd.Completed
-
Sihuan Pharmaceutical Holdings Group Ltd.CompletedHealthy Male Volunteers
-
Xuanzhu Biopharmaceutical Co., Ltd.Not yet recruitingGastrointestinal Diseases | Gastroesophageal Reflux | Esophageal Motility Disorders | Deglutition Disorders | Esophageal Diseases | Esophagitis | Reflux EsophagitisChina
-
Sihuan Pharmaceutical Holdings Group Ltd.Unknown
-
Sihuan Pharmaceutical Holdings Group Ltd.Completed
-
Sihuan Pharmaceutical Holdings Group Ltd.CompletedHealthy VolunteersChina
-
University of DelawareCompletedBlood Pressure | Cerebrovascular ReactivityUnited States
-
Institut d'Anesthesiologie des Alpes MaritimesUniversité de Nice Sophia Antipolis; Medical University of GrenobleCompleted